Last reviewed · How we verify
NCT02853097
Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients
trial testing Cytology Specimen Collection Procedure in Hormone-Resistant Prostate Cancer in 7 participants. Terminated before completion.
27 September 2020
Quick facts
| Lead sponsor | University of Southern California |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 7 |
| Start date | 14 June 2016 |
| Primary completion | 27 September 2020 |
| Estimated completion | 27 September 2020 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- Cytology Specimen Collection Procedure
- Laboratory Biomarker Analysis — full drug profile →
Conditions studied
- Hormone-Resistant Prostate Cancer — all drugs for Hormone-Resistant Prostate Cancer →
- Metastatic Prostate Carcinoma — all drugs for Metastatic Prostate Carcinoma →
- Prostate Adenocarcinoma — all drugs for Prostate Adenocarcinoma →
Sponsor
University of Southern California
Who can join
18 and older, male only, with Hormone-Resistant Prostate Cancer or Metastatic Prostate Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research trial studies cell-free deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in blood from patients with prostate cancer that does not respond to hormone therapy and has spread to other places in the body. Studying samples of blood from patients with prostate cancer may help doctors to learn more about the changes that occur in tumor cells over time and how they become resistant to anti-cancer drugs.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Androgen receptor splice variants and prostate cancer: From bench to bedside.
Wadosky KM, Koochekpour S. · · 2017 · cited 98× · PMID 28077788 · DOI 10.18632/oncotarget.14537 -
The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches.
Alarcón-Zendejas AP, Scavuzzo A, Jiménez-Ríos MA, Álvarez-Gómez RM, et al · · 2022 · cited 60× · PMID 35422101 · DOI 10.1038/s41391-022-00537-2 -
Diagnostic and Therapeutic Potential of Circulating-Free DNA and Cell-Free RNA in Cancer Management.
Hassan S, Shehzad A, Khan SA, Miran W, et al · · 2022 · cited 17× · PMID 36009594 · DOI 10.3390/biomedicines10082047 -
Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer.
Di Nunno V, Gatto L, Santoni M, Cimadamore A, et al · · 2018 · cited 15× · PMID 30319966 · DOI 10.3389/fonc.2018.00397
Verify or expand the search:
- PubMed search for NCT02853097
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cytology Specimen Collection Procedure
Trials testing the same drug.
- NCT04142385 — Incidence of HIV Infection in Screening Indian Men Who Have Sex With Men · withdrawn
- NCT04142398 — Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men · withdrawn
- NCT04526587 — Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors · recruiting
- NCT02514408 — Circulating Tumor Cells in Operative Blood in Patients With Bladder Cancer · withdrawn
- NCT03057626 — Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma · active not recruiting
Other recruiting trials for Hormone-Resistant Prostate Cancer
Currently open trials in the same condition.
- NCT02881242 — Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer · Phase 2 · active not recruiting
- NCT02312557 — Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzaluta · Phase 2 · active not recruiting
- NCT01953640 — Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy · active not recruiting
Other University of Southern California trials
Trials by the same sponsor.
- NCT07288463 — Hearing Loss and Genetic Risks for Alzheimer's Disease and Related Dementia · NA · not yet recruiting
- NCT05914233 — Non-invasive Ultrasound Retinal Stimulation for Vision Restoration · NA · not yet recruiting
- NCT06163664 — Role of ChatGPT in Vestibular Schwannoma Management · NA · withdrawn
- NCT07332312 — A Culturally Informed Patient Navigation Program (CFPN) to Reduce Delays Between Diagnosis and Treatment in American Ind · NA · not yet recruiting
- NCT07290478 — Encouraging Older Adults and Adults With Serious Illness to Designate a Health Care Proxy · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02853097 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Southern California
- Last refreshed: 5 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02853097.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing